Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

The approval was based on results from a Phase IIb trial demonstrating a 15.5-month median overall survival on Ziihera.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.